Cutacnyl 5%

Quick links to important sections

Cutacnyl 5%

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cutacnyl 5%

What is Cutacnyl 5%?

Cutacnyl 5% is a topical dermatological treatment formulated to address common forms of acne. It belongs to a class of medications known as oxidizing agents, which are applied directly to the skin to manage inflammatory and non-inflammatory lesions.

Composition and Active Ingredient

The therapeutic effect of Cutacnyl 5% is derived from its active substance, benzoyl peroxide, at a concentration of 5%. This concentration is often utilized for individuals with moderate acne or those whose skin has shown tolerance to lower strengths. The medication is typically presented in a water-based gel form, designed to facilitate absorption into the skin's pores while minimizing excessive greasiness.

Mechanism of Action

Cutacnyl 5% functions through several biological pathways to target the underlying causes of acne:

  • Antimicrobial Activity: It releases active oxygen upon application, which helps to reduce the population of Cutibacterium acnes, the bacteria primarily responsible for acne inflammation. Unlike antibiotics, it does not induce bacterial resistance.
  • Keratolytic Effect: It works to soften and shed the outer layer of the skin. This process helps to prevent the accumulation of dead skin cells that can clog pores and lead to the formation of comedones (whiteheads and blackheads).
  • Sebostatic Action: The formulation assists in reducing the production of excess sebum, the natural skin oil that, when produced in surplus, contributes to the development of acne lesions.

Therapeutic Purpose

The primary objective of using Cutacnyl 5% is to decrease the number and severity of acne sores. It is used to treat acne vulgaris on the face, back, or chest. By addressing both the bacterial presence and the physical blockage of pores, the treatment aims to clear existing blemishes and prevent the emergence of new ones.

What side effects are possible with Cutacnyl 5%?

Possible Side Effects and Safety Information

The safety profile of topical Benzoyl Peroxide, the active ingredient in Cutacnyl 5%, is primarily characterized by adverse reactions affecting the Skin and Subcutaneous Tissue system. These are typically localized effects consistent with its regulatory classification as a topical antiacne agent.


Frequency-Classified Adverse Reactions

The most frequent adverse events are classified in regulatory documents as Very Common or Common and involve the application site:

  • Application Site Reactions: These include erythema (redness), dryness or xerosis, scaling or peeling, pruritus (itching), and pain (including stinging or burning sensation).

A key safety pattern noted is that this localized irritation is most likely to occur and increase during the first few weeks of treatment and commonly lessens with continued use.


Serious Reactions and Safety Constraints

Serious adverse reactions affecting the Immune System are documented as rare, reported primarily through post-marketing surveillance. These reactions include severe hypersensitivity events such as Anaphylaxis and Angioedema.

Official regulatory sources also document important safety constraints:

  • Photosensitivity: Benzoyl Peroxide may lead to increased sensitivity to ultraviolet light, necessitating avoidance of excessive sun exposure.
  • Compromised Skin: The product should not be applied to skin areas that are compromised, such as those with cuts, abrasions, active sunburn, or eczema.
  • Population Status: Due to minimal systemic absorption, the medication is not expected to result in fetal exposure during maternal use. It is not known if it is excreted in human milk.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for topical Benzoyl Peroxide (Cutacnyl 5%) defines an overdose scenario primarily through localized reactions following excessive skin application. Officially documented information confirms that due to the substance's minimal systemic absorption, overdose from topical overuse is not generally expected to produce systemic effects.

Documented Overdose Manifestations and Actions

The application of excessive quantities of the gel will not result in faster or better therapeutic results but may lead to a localized overdose presentation. The officially recognized manifestations of topical overdose are severe local irritation, including the development of swelling or blistering at the application site.

If severe irritation, swelling, or blistering occurs, the regulatory procedure mandates immediate discontinuation of use.

Situation
Accidental Ingestion
Immediate Medical Attention is required if the product is accidentally swallowed, as stated in official labeling.
Topical Overuse
Discontinue use immediately if severe irritation, swelling, or blistering develops. Management involves appropriate symptomatic therapy, such as the use of cold compresses, as no specific antidote is listed in regulatory documentation.

Urgent medical help must be sought in the event of accidental ingestion.

Therapeutic Uses of Cutacnyl 5%

What Cutacnyl 5% Treats: Main Uses and Benefits

Cutacnyl 5% is a topical treatment that is commonly used to manage acne vulgaris in its mild to moderate forms. It is applied in addressing symptoms that cluster into patterns of noninflammatory lesions and smaller inflammatory lesions. This includes managing the appearance of blackheads, whiteheads, papules, and pustules. The gel provides supportive therapeutic benefit by playing a role in managing the acute appearance of existing lesions while simultaneously contributing to support for new breakout control. This action offers symptomatic relief that helps patients cope more steadily with recurrent or persistent breakouts.


Quick Fact: Relief for Acne Lesions


The product contributes to improved comfort during periods of heightened symptoms and stability during symptomatic phases. As part of symptomatic management, the product supports the patient during difficult episodes by easing distress. This continuous support may assist with maintaining functional stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Population Eligibility and Official Restrictions

The eligibility profile for Cutacnyl 5% is defined by governmental regulatory documents, identifying specific populations for whom use is permitted, restricted, or explicitly contraindicated.

Classification Eligible Population Restriction Basis
Standard Use Adults and Adolescents Generally established for those 12 years and older.
Use Not Recommended Children under 12 years Safety and efficacy are not officially established for this pediatric group.

Contraindicated Populations

The gel must not be used by individuals with a known hypersensitivity (allergy) to the active substance, Benzoyl Peroxide, or to any of the other ingredients in the formulation. Use is also prohibited on areas where the skin is already compromised, such as open cuts, scrapes, sunburned, or eczematous skin, or near mucous membranes like the eyes, mouth, and nostrils.

Special Population Restrictions

Status Regulatory Statement Requirement
Pregnancy Conditional Use Permitted if the benefit is determined to outweigh the potential risk, consistent with minimal systemic absorption.
Lactation Conditional Use Permitted with caution; must not be applied to the chest or any area where the nursing infant may have direct contact.

No specific restrictions related to renal or hepatic impairment are documented in the official labeling, which aligns with the medicine's topical application and minimal systemic absorption.

What should I know about interactions with other medicines?

The interaction profile for Cutacnyl 5% (Benzoyl Peroxide) is defined primarily by its topical pharmacodynamic effects. Minimal systemic absorption is documented in regulatory labeling, which results in a lack of known clinically significant systemic drug–drug interactions, such as those involving CYP enzymes or drug transporters. Interactions are therefore localized and involve specific topical agents or substances.

The following interaction patterns and official constraints are documented:

Interacting Substance/Class Documented Interaction Outcome Regulatory Constraint
Topical Retinoids (Tretinoin, Tazarotene, Isotretinoin) Reduction in their efficacy due to oxidative degradation. Mandatory Timing Rule: Must be applied at different times of the day (e.g., morning and evening).
Topical Sulfone Products (e.g., Dapsone) Risk of temporary yellow or orange discoloration of the skin and hair. Use with caution; separation advised to mitigate aesthetic effect.
Peeling, Abrasive, or Drying Agents Risk of a cumulative irritancy effect on the skin. Use with caution; avoid co-administration with high-concentration alcohol or astringents.

Co-administration with photosensitizing agents may increase the photosensitizing effect, requiring caution. These constraints structure the official interaction guidance, focusing entirely on avoiding compound skin irritation or loss of therapeutic efficacy of co-administered topical agents.

Mechanism of Action

The mechanism of Cutacnyl 5% (Benzoyl Peroxide) involves two primary, concurrent mechanistic domains that modify the biological environment within the pilosebaceous unit through chemical interaction rather than specific receptor binding.

The Oxidative Antimicrobial Mechanism

This domain focuses on the drug's interaction with the bacterial target, extitCutibacterium acnes ( extitC. acnes). BPO decomposes upon topical application, releasing Reactive Oxygen Species (ROS), which are powerful, non-specific oxidizing agents. This mechanism directly destroys the bacteria by damaging its cellular components and simultaneously introducing oxygen into the follicle, which is toxic to the anaerobic extitC. acnes. This mechanism leads to a decrease in the bacterial population, which attenuates the associated inflammatory signaling.

The Keratolytic and Desquamative Mechanism

This mechanism involves a direct chemical interaction with the structural cells lining the follicle. BPO acts as a mild keratolytic agent, disrupting the cohesion of the keratinized cells and promoting their accelerated shedding, a process called desquamation. By chemically facilitating the disaggregation of cellular material, this action results in the physical clearing of the follicular opening and supports the rate of epithelial cell turnover.

Dosage and Administration Information

Cutacnyl 5% is strictly formulated for Topical Administration as an aqueous gel, meaning the medicine is applied only externally to the affected skin areas. The official usage protocol requires a specific sequence of preparation and application.

The skin must be thoroughly cleansed and dried immediately before each application of the gel. The labeled regimen requires applying a thin layer to the entire affected area. The initial schedule typically begins with once daily use, to allow for the assessment of skin tolerance.

The application frequency is designed to be adaptable. If the initial schedule is well-tolerated, the frequency may be gradually increased to twice daily or up to three times daily. This titration strategy is defined to allow for patient-specific adjustment based on individual skin response.

Age-specific use rules specify that safety and effectiveness in children younger than 12 years of age have not been fully established, and use in this population must be determined by a healthcare provider. The usage is also defined by time-based parameters: initial clinical improvement is expected to commence within four weeks, with the full therapeutic effect typically observed after approximately eight to twelve weeks of continuous use.

Procedurally, the product must be kept away from eyes, mouth, and mucous membranes during application. Furthermore, the gel requires cautious handling to avoid contact with hair and dyed fabrics (e.g., clothing, bedding), as the product carries a risk of bleaching or discoloration.

Recent Clinical Evidence

Research evidence / Overview of Studies for Cutacnyl 5%

Evidence Base for Mild to Moderate Acne Vulgaris

Research examining the use of the active ingredient in Cutacnyl 5% focuses primarily on mild to moderate acne vulgaris. These research efforts include multiple short-term, controlled clinical trials, where the product was compared against a vehicle (an inactive gel base). Scientists have compiled and analyzed these individual studies in larger systematic reviews to understand the overall findings.

Studies were conducted using objective measures of skin changes, focusing on measuring the change in the number of total acne spots (inflammatory and non-inflammatory) on the skin. Findings describe patterns observed in the studies over typical 8 to 12-week trial periods, and research highlights changes measured by assessing the proportion of participants whose overall acne severity score moved into a 'clear' or 'almost clear' category.


Research on Inflammatory Lesion Outcomes

Studies have also explored the specific patterns of the active ingredient on inflammatory lesions, such as papules and pustules. The research examined changes in inflammatory lesion counts and monitored the quantity of Cutibacterium acnes bacteria present on the skin, as the ingredient was studied for its relationship to this bacteria. It is important to note that a significant portion of the evidence was studied alongside other agents, such as topical retinoids or antibiotics, in fixed-dose combination product trials. Research focusing solely on the 5% monotherapy is limited when compared to the combination product data.


Long-Term Research and Follow-up Durations

Most primary efficacy trials are short-term in nature, generally observing responses over defined time intervals of 8 to 12 weeks. While some controlled trials have tracked outcomes up to 52 weeks, demonstrating that reductions in lesion counts were maintained, the high-quality, controlled evidence needed to fully establish long-term effects is not fully established across all products containing the active ingredient. Therefore, follow-up durations were limited in many of the key trials.


Evidence in Specific Age Groups and Populations

The research exploring short-term symptom changes was primarily evaluated in specific populations, namely adolescents aged 12 and older and adults. For populations outside of this core group—such as children under 12 years of age—data are still emerging, and evidence is limited. Similarly, research exploring the use of the active ingredient in individuals with certain complex health situations or comorbidities is not widely available in the published trial reports. This means that data for certain groups remain insufficient, and findings describe group patterns related only to the populations studied.


Understanding Evidence Gaps and Areas of Uncertainty

While the active ingredient has been studied extensively, there are areas where clarity remains low. One key limitation is that evidence quality varies across studies, and some comparisons between the 5% concentration and other single-agent acne treatments are lacking. This lack of high-certainty comparative evidence means the extent of differences between treatments is not fully established. Furthermore, as noted above, long-term effects are not fully established by high-quality randomized studies. Research provides context but not individual predictions, and studies help show what has been observed so far, but do not determine whether an individual will respond similarly.

Key Studies & References

  1. Benzoyl Peroxide - StatPearls (NCBI Bookshelf)

Frequently Asked Questions (FAQ)

Common questions about Cutacnyl 5% (FAQ)


Q: How quickly should I expect to see results from Cutacnyl 5%?

A: According to official product information, initial signs of clinical improvement are generally expected to begin within four weeks of continuous use. The full therapeutic effect is typically observed after approximately eight to twelve weeks. The medicine requires consistent application to align with the response patterns observed in studies.


Q: What are the most common reported side effects of Cutacnyl 5%?

A: The most frequent adverse events described in official documents are localized skin reactions at the site of application. These commonly include redness (erythema), dryness, scaling or peeling, itching, and a burning sensation. These effects are most likely to occur and increase during the initial weeks of treatment, but they often lessen as the skin adjusts to the medication.


Q: Is it normal for my skin to peel a little when starting Cutacnyl 5%?

A: Yes, scaling or peeling is listed in regulatory documents as a very common skin-related effect of the active ingredient. Because the medication has a keratolytic action (promoting the shedding of surface skin cells), this kind of localized irritation and peeling often occurs or increases during the first few weeks of using the gel.


Q: Is the 5% strength appropriate for someone who has never used benzoyl peroxide before?

A: The 5% concentration is one of the concentrations available for this active ingredient. Information regarding the use of topical benzoyl peroxide, in general, describes a strategy of gradual introduction, such as applying sparingly or using a reduced frequency, to allow skin tolerance to be assessed. Increased irritation beyond expected levels may signal the need to use a lower concentration.


Q: What is the maximum time a person can continuously use Cutacnyl 5% according to official guidance?

A: Most primary clinical trials that established efficacy observed patients over defined intervals of 8 to 12 weeks, although some controlled trials have tracked outcomes for up to 52 weeks (one year). Official guidance does not universally establish a specific maximum continuous duration, but long-term data focuses on the maintenance of effects over a period of many months.


Q: Is Cutacnyl 5% the same as other benzoyl peroxide products?

A: Cutacnyl 5% is specifically an aqueous gel formulation containing 5% Benzoyl Peroxide. Other benzoyl peroxide products may contain different strengths (e.g., 2.5% or 10%) or may be in a different form (e.g., a cream or wash). These differences in strength and formulation are factors that may influence the product's effect and potential for localized skin irritation.


Q: Can I use other topical skin care products at the same time as Cutacnyl 5%?

A: Official warnings strongly advise against the co-administration of peeling, abrasive, or drying agents, including high-concentration alcohol or astringents, because of the risk of cumulative skin irritation. General skincare products are not part of the interaction warnings, but it is noted that combining topicals can increase the chance of skin dryness or localized irritation, depending on the product ingredients.


Q: Can Cutacnyl 5% cause my skin to become more sensitive to the sun?

A: Yes, regulatory documents note that Benzoyl Peroxide may lead to increased sensitivity to ultraviolet (UV) light, known as photosensitivity. Official guidance advises limiting unnecessary or excessive sun exposure, including sunlamps and tanning beds, and recommends the use of a suitable sunscreen and protective clothing while using the product.


Q: Is there a rebound effect, meaning acne gets worse after stopping Cutacnyl 5%?

A: Official research summaries examine how well the product maintains reductions in acne over time, but do not explicitly use the term 'rebound effect' after treatment discontinuation. Clinical data related to maintenance of effects suggest that continued application may be considered for the management of acne, consistent with the chronic nature of the condition.


Q: Can Cutacnyl 5% bleach clothing or bed linens?

A: Yes, official guidance and product warnings state that the active ingredient can act as an oxidizing agent and carries a risk of bleaching or discoloring fabrics. Cautious handling is required to avoid contact with hair, colored clothing, or bedding when applying the gel.


Q: How is Cutacnyl 5% different from a lower concentration of benzoyl peroxide?

A: The 5% concentration refers to the precise strength of the active ingredient. Research indicates that higher concentrations, such as 5% and 10%, are associated with a greater potential for localized skin irritation, including redness, excessive drying, and peeling, when compared to lower concentrations.


Q: Can men and women use Cutacnyl 5% equally?

A: Yes, the standard eligibility for Cutacnyl 5% is defined for Adults and Adolescents, generally those 12 years and older, without any distinction or restriction based on the user's gender.


Q: Is Cutacnyl 5% safe to use on parts of the body other than the face?

A: The medicine is classified for topical administration and is generally applied to the affected areas of the skin, which commonly includes the face or trunk. However, its use is prohibited on compromised skin (cuts, scrapes, sunburn) and near mucous membranes (eyes, mouth, nostrils).


Q: Are there any known interactions between Cutacnyl 5% and oral antibiotics for acne?

A: The official interaction profile is defined by topical agents, as the medicine has documented minimal systemic absorption. For this reason, official regulatory documents indicate a lack of known significant systemic drug-drug interactions involving common oral medications.


Q: Can I use makeup after applying Cutacnyl 5%?

A: While official guidance does not specifically address makeup use for the monotherapy gel, general patient information for similar topical treatments often describes applying cosmetics, like other facial creams or makeup, only after the prescribed topical gel has been applied and allowed to dry completely.


Q: Can I use other medicated creams to the same area as Cutacnyl 5%?

A: Official documentation indicates that using multiple topical acne treatments in the same area should be done with caution. Combining them increases the risk of excessive skin irritation, dryness, and peeling.


Q: Are there any food or diet restrictions related to using Cutacnyl 5%?

A: Due to the medicine's topical application and its documented minimal systemic absorption into the bloodstream, official regulatory documents do not define or mention specific restrictions related to food or diet.


Q: What kind of studies were conducted on Cutacnyl 5%?

A: Research on the active ingredient is based primarily on short-term, controlled clinical trials where the product was compared against an inactive gel base. These studies tracked objective measures, such as the change in the total count of inflammatory and non-inflammatory acne spots on the skin.


Q: How can I tell the difference between a normal side effect and an allergic reaction to Cutacnyl 5%?

A: Normal common side effects are localized skin irritation like redness, dryness, and peeling. Serious, rare adverse reactions are documented as severe hypersensitivity events, which might include swelling of the face, lips, tongue, or throat (angioedema). Any severe reaction should be promptly assessed by a healthcare professional.


Q: Is it common to experience initial worsening of acne when starting Cutacnyl 5%?

A: Some patient information documents note that skin irritation, characterized by redness and peeling, may seem to increase before visible improvement occurs. This initial irritation is most likely to occur in the first few weeks of treatment as the skin adjusts to the medication.


Q: Does Cutacnyl 5% penetrate deep into the skin?

A: The medicine is designed as a topical antiacne agent and acts primarily on the surface layers of the skin and within the hair follicles (pilosebaceous unit). Regulatory documents confirm it has minimal systemic absorption, indicating its action is localized to the skin.


Q: What does official guidance say about using Cutacnyl 5% during lactation?

A: Conditional use is permitted with caution during lactation. Official information indicates that the medicine should not be applied to the chest or any area where direct contact with the nursing infant is possible, and proper hand hygiene is noted after application.


Q: Are there different formats of Cutacnyl 5%, like gel or cream?

A: The formulation of Cutacnyl 5% is specifically defined as an aqueous gel. This is a hydrophilic topical preparation designed for direct, non-occlusive application to the skin.


Q: How should I store Cutacnyl 5% to maintain its effectiveness?

A: Regulatory guidelines state that the gel should be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The product requires protection from freezing, excessive heat, and direct sunlight, and the container is specified to be kept tightly closed.


Q: Is Cutacnyl 5% effective against blackheads and whiteheads?

A: The medicine is known for its keratolytic mechanism, which helps promote the clearing of follicular openings, making it relevant for non-inflammatory lesions (blackheads and whiteheads). Research studies track changes in total acne spots, which includes both inflammatory and non-inflammatory lesions.


Q: What information is available regarding the long-term use of Cutacnyl 5%?

A: Most primary trials are short-term (8 to 12 weeks). While some studies have followed patients up to 52 weeks, showing that reductions in lesions were maintained, the high-quality, controlled evidence needed to fully establish long-term effects and safety across all populations is noted as not fully established.


Q: Is Cutacnyl 5% known to cause hyperpigmentation in darker skin tones?

A: Official research summaries indicate that data exploring the use of the active ingredient in certain specific populations is limited. The evidence base for long-term effects on various skin tones, including potential for hyperpigmentation, is not widely available in the primary published trial reports.


Q: What is the role of the excipients (non-active ingredients) in Cutacnyl 5%?

A: Excipients are the non-active ingredients that make up the medicine’s base formulation. For Cutacnyl 5%, this includes the aqueous gel base, which helps facilitate the efficient distribution of the active compound (Benzoyl Peroxide) to the site of action. Some excipients may also be noted for their role in stability or preservation.

How should Cutacnyl 5% be stored and disposed of?

Storage and Disposal Requirements for Cutacnyl 5% (Benzoyl Peroxide)

Official regulatory guidelines for Cutacnyl 5% (benzoyl peroxide gel) establish precise requirements for storage and handling to maintain product quality and safety.


Mandatory Storage Conditions

The gel must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). It is essential to protect the product from freezing and exposure to excessive heat or direct sunlight. The container must be kept tightly closed to prevent contamination and maintain stability. Additionally, the medication must be stored out of the reach of children to prevent accidental ingestion or misuse.

Disposal Instructions

Expired or unused product must be disposed of safely according to local regulations. Benzoyl peroxide is generally not recommended for disposal by flushing down the toilet or pouring into a drain; instead, it should be disposed of in the trash after being sealed in a bag or taken to an authorized drug take-back location.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cutacnyl 5% found in:

A-Z Index: